van Hartingsveldt, Bart <br/><br/>
Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.  [electronic resource] 

 -  British journal of clinical pharmacology  May 2013 
 - 1289-98 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2125 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2125.2012.04477.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Cutaneous<br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Area Under Curve<br/>Dose-Response Relationship, Drug<br/>Female<br/>Half-Life<br/>Humans<br/>Injections, Intravenous<br/>Interleukin-13--immunology<br/>Male<br/>Middle Aged<br/>Time Factors<br/>Young Adult